Activation of calcineurin in human failing heart ventricle by endothelin-1, angiotensin II and urotensin II

British Journal of Pharmacology

Volumn 145, Issue 4, 2005, Pages 432-440

  Li, Joan ^a,b   Wang, Jianchun ^a,c   Russell, Fraser D ^a,d   Molenaar, Peter ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c SHANDONG UNIVERSITY   (China)

^d UNIVERSITY OF THE SUNSHINE COAST   (Australia)

Author keywords

Calcineurin; Heart failure; Hypertrophy; Receptors; Signal transduction

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CALCINEURIN; CARVEDILOL; CLOPIDOGREL; DIGOXIN; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; ENDOTHELIN 1; G PROTEIN COUPLED RECEPTOR; HYDRALAZINE; METOPROLOL; MILRINONE; MUSCARINIC RECEPTOR BLOCKING AGENT; NITRATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PERHEXILINE; PHOSPHATE; PROTEIN KINASE C EPSILON; PROTON PUMP INHIBITOR; SPIRONOLACTONE; TACROLIMUS; UNINDEXED DRUG; UROTENSIN II; WARFARIN;

ADULT; ARTICLE; BECKER MUSCULAR DYSTROPHY; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DRUG EFFECT; EXPLANT; FEMALE; FONTAN PROCEDURE; HEART FAILURE; HEART MUSCLE CONTRACTILE FORCE; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN TISSUE; INCUBATION TIME; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RHEUMATIC DISEASE; SIGNAL TRANSDUCTION;

ADULT; ANGIOTENSIN II; BLOTTING, WESTERN; CALCINEURIN; ENDOTHELIN-1; FEMALE; HEART FAILURE, CONGESTIVE; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; PEPTIDES; PHOSPHATES; PROTEIN KINASE C; TACROLIMUS; UROTENSINS;

EID: 22044453982     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706217     Document Type: Article

References (41)

1. BRAUNWALD, E. & BRISTOW, M.R. (2000). Congestive heart failure: fifty years of progress. Circulation, 102, IV-14-IV-23.
2. BURRELL, K.M., MOLENAAR, P., DAWSON, P.J. & KAUMANN, A.J. (2000). Contractile and arrhythmic effects of endothelin receptor agonists in human heart in vitro: blockade with SB 209670. J. Pharmacol. Exp. Ther., 292, 449-459.
3. DIEDRICHS, H., CHI, M., BOELCK, B., MEHLHORM, U. & SCHWINGER, R.H.G. (2004). Increased regulatory activity of the calcineurin/NFAT pathway in human heart failure. Eur. J. Heart Fail., 6, 3-9.
4. 2+ response amplitude and duration. Nature, 386, 855-858.
5. DOUGLAS, S.A., TAYARA, L., OHLSTEIN, E., HALAWA, N. & GIAID, A. (2002). Congestive heart failure and expression of myocardial urotensin II. Lancet, 359, 1990-1997.
6. GOLDSPINK, P.H., MCKINNEY, R.D., KIMBALL, V.A., GEENAN, D.L. & BUTTRICK, P.M. (2001). Angiotensin II induced cardiac hypertrophy in vivo is inhibited by cyclosporin A in adult rats. Mol. Cell. Biochem., 226, 83-88.
7. HARDER, K.W., OWEN, P., WONG, L.K., AEBERSOLD, R., CLARK-LWEIS, I. & JIRIK, F.R. (1994). Characterization and kinetic analysis of the intracellular domain of human protein tyrosine phosphatase beta (HPTP beta) using synthetic phosphopeptides. Biochem. J., 298, 395-401.
8. 2+/calmodulin-dependent protein kinase II and protein kinase C. J. Biol Chem., 264, 16524-16529.
9. HERGET, T., OEHRLEIN, S.A., PAPPIN, D.J., ROZENGURT, E. & PARKER, P.J. (1995). The myristoylated alanine-rich C-kinase substrate (MARCKS) is sequentially phosphorylated by conventional, novel and atypical isotypes of protein kinase C. Eur. J. Biochem., 233, 448-457.
10. JOHNS, D.G., AO, Z., NASELSKY, D., HEROLD, C.L., MANISCALCO, K., SAROV-BLAT, L., STEPLEWSKI, K., AIYAR, N. & DOUGLAS, S.A. (2004). Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn-Schmiedeberg's Arch. Pharmacol., 370, 238-250.
11. 2-adrenergic receptors hastens relaxation and mediates phosphorylation of phospholamban, troponin I and C-protein in ventricular myocardium from patients with terminal heart failure. Circulation, 99, 65-72.
12. LIM, H.W. & MOLKENTIN, J.D. (1999). Calcineurin and human heart failure. Nat. Med., 5, 246-247.
13. MALBON, C.C., TAO, J. & WANG, H.Y. (2004). AKAPs (A-kinase anchoring proteins) and molecules that compose their G-protein-coupled receptor signalling complexes. Biochem. J., 379, 1-9.
14. MARTIN, B., PALLEN, C.J., WANG, J.H. & GRAVES, D.J. (1985). Use of fluorinated tyrosine phosphates to probe the substrate specificity of the low molecular weight phosphatase activity of calcineurin. J. Biol. Chem., 260, 14932-14937.
15. MCMURRAY, J.J.V., ÖSTERGREN, J., SWEDBERG, K., GRANGER, C.G., HELD, P., MICHELSON, E.L., OLOFSSON, B., YUSUF, S., PFEFFER, M.A. & (for the CHARM investigators and committees) (2003). Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet, 362, 767-771.
16. MCMURRAY, J.J., RAY, S.G., ABDULLAH, I., DARGIE, H.J. & MORTON, J.J. (1992). Plasma endothelin in chronic heart failure. Circulation, 85, 1375-1379.
17. MENARD, J., BOGER, R.S., MOYSE, D.M., GUYENE, T.T., GLASSMAN, H.N. & KLEINERT, H.D. (1995). Dose-dependent effects of the renin inhibitor zankiren HCL after a single oral dose in mildly sodium-depleted normotensive subjects. Circulation, 91, 330-338.
18. MENDE, U., COHEN, A.K., ARAMBURU, J., SCHOEN, F.J. & NEER, E.J. (1998). Transient cardiac expression of constitutively active Gαq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc. Natl. Acad. Sci. U.S.A., 95, 13893-13898.
19. s-protein. Circulation, 102, 1814-1821.
20. MOLKENTIN, J.D., LU, J.-R., ANTOS, C.L., MARKHAM, B., RICHARDSON, J., ROBBINS, J., GRANT, S.R. & OLSEN, E.N. (1998). A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell, 93, 215-228.
21. MORAVEC, C.S., SCHLUCHTER, M.D., PARANANDI, L., CZERSKA, B., STEWART, R.W., ROSENKRANZ, E. & BOND, M. (1990). Inotropic effects of angiotensin II on human cardiac muscle in vitro. Circulation, 82, 1973-1984.
22. NISHIKAWA, K., TOKER, A., JOHANNES, F.-J., SONGYANG, Z. & CANTLEY, L.C. (1997). Determination of the specific substrate sequence motifs of protein kinase C isozymes. J. Biol. Chem., 272, 952-960.
23. PFEFFER, M.A., SWEDBERG, K., GRANGER, C.B., HELD, P., MCMURRAY, J.J.V., MICHELSON, E.L., OLOFSSON, B., ÖSTERGREN, J., YUSUF, S. & (for the CHARM investigators and committees) (2003). Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, 362, 759-766.
24. RITTER, O., HACK, S., SCHUH, K., RÖTHLEIN, N., PERROT, A., OSTERZIEL, K.J., SCHULTE, H.D. & NEYSES, L. (2002). Calcineurin in human heart hypertrophy. Circulation, 105, 2265-2269.
25. ROUSSEAU, M.F., GURNÉ, O., DUPREZ, D., VAN MIEGHEM, W., ROBERT, A., AHN, S., GALANTI, L. & KETELSLEGERS, J.-M. (2002). Beneficial neurohormonal profile of spironolactone in severe congestive heart failure. Results from the RALES neurohormonal substudy. J. Am. Coll. Cardiol, 40, 1596-1601.
26. RUSSELL, F.D. (2004). Emerging roles of urotensin-II in cardiovascular disease. Pharmacol. Ther., 103, 223-243.
27. RUSSELL, F.D., MEYERS, D., GALBRAITH, A.J., BETT, N., TOTH, I., KEARNS, P. & MOLENAAR, P. (2003). Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am. J. Physiol. Heart Circ. Physiol., 285, H1576-H1581.
28. RUSSELL, F.D. & MOLENAAR, P. (2000). The human heart endothelin system: ET-1 synthesis, storage, release and effect. Trends Pharmacol. Sci., 21, 353-359.
29. RUSSELL, F.D. & MOLENAAR, P. (2004). Investigation of signalling pathways that mediate the inotropic effect of urotensin-II in human heart. Cardiovasc. Res., 63, 673-681.
30. RUSSELL, F.D., MOLENAAR, P. & O'BRIEN, D.M. (2001). Cardiostimulant effects of urotensin-II in human heart in vitro. Br. J. Pharmacol., 132, 5-9.
31. SAKAI, S., MIYAUCHI, T., KOBAYASHI, M., YAMAGUCHI, I., GOTO, K. & SUGISHITA, Y. (1996). Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature, 384, 353-355.
32. 1-adrenoceptor. Naunyn-Schmiedeberg's Arch. Pharmacol., 367, 10-21.
33. SEKI, K., CHEN, H.-C. & HUANG, K.-P. (1995). Dephosphorylation of protein kinase C substrates, neurogranin, neuromodulin, and MARCKS, by calcineurin and protein phosphatases 1 and 2A. Arch. Biochem. Biophys., 316, 673-679.
34. SHIN, H.G., BARNETT, J.V., CHANG, P., REDDY, S., DRINKWATER, D.C., PIERSON, R.N., WILEY, R.G. & MURRAY, K.T. (2000). Molecular heterogeneity of protein kinase C expression in human ventricle. Cardiovasc. Res., 48, 285-299.
35. TAIGEN, T., DE WINDT, L.J., LIM, H.W. & MOLKENTIN, J.D. (2000). Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc. Natl. Acad. Sci. U.S.A., 97, 1196-1201.
36. TSAO, L., NEVILLE, C., MUSARO, A., MCCULLAGH, K.J.A. & ROSENTHAL, N. (2000). Revisiting calcineurin and human heart failure. Nat. Med., 6, 2-3.
37. TUNG, H.Y. (1986). Phosphorylation of the calmodulin-dependent protein phosphatase by protein kinase C. Biochem. Biophys. Res. Commun., 138, 783-788.
38. TZANIDIS, A., HANNAN, R.D., THOMAS, W.G., ONAN, D., AUTELITANO, D.J., SEE, F., KELLY, D.J., GILBERT, R.E. & KRUM, H. (2003). Direct actions of urotensin II on the heart. Implications for cardiac fibrosis and hypertrophy. Circ. Res., 93, 246-253.
39. WAGNER, O.F., CHRIST, G., WOJTA, J., VIERHAPPER, H., PARZER, S., NOWOTNY, P.J., SCHNEIDER, B., WALDHÄUSL, W. & BINDER, B.R. (1992). Polar secretion of endothelin-1 by cultured endothelial cells. J. Biol. Chem., 267, 16066-16068.
40. 11 in cardiomyocytes. Nat. Med., 7, 1236-1240.
41. YOSHIDA, H., TAKAHASHI, M., TANONAKA, K., MAKI, T., NASA, Y. & TAKEO, S. (2001). Effects of ACE inhibition and angiotensin II type 1 receptor blockade on cardiac function and G proteins in rats with chronic heart failure. Br. J. Pharmacol., 134, 150-160.